Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Geneseeq Completes $114 Million Funding for Cancer Genetic Sequencing

publication date: Dec 27, 2019

Geneseeq, a Nanjing-Toronto company that offers genetic sequencing tests for cancer, completed a $114 million Series D financing led by China Reform Holdings Corporation. Geneseeq uses next-gen sequencing to provide decision-making tools for physicians. The company describes its pan-genomic test as a precision medicine support system for targeted drugs, immunotherapies and cancer risk assessment. The Geneseeq Prime test detects genetic abnormalities in 425 cancer-related genes. Lilly Asia Ventures and SoftBank China Venture Capital also participated in this round. In the three previous fundings, Geneseeq raised a total of $86 million. More details...

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital